Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation

NCT05263947 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Bevacizumab
Tyrosine Kinase Inhibitor
EGFR L858R

Interventions

DRUG: Bevacizumab
DRUG: Icotinib

Sponsor

Tianjin Medical University Cancer Institute and Hospital